New Delhi, May 11 (IANS) A new report has said that the human immunodeficiency virus (HIV) market across the seven major markets is forecast to grow at a compound annual growth rate (CAGR) of 1.9 per cent from $26.5 billion in 2023 to $32.1 billion in 2033.
The GlobalData’s report, “Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast,” reveals that market growth will primarily be driven by the increased uptake of long-acting injectable therapies, as well as the anticipated launch of novel single tablet regimens (STRs).
“The pipeline analysis indicates a shift away from 3-drug STRs and towards 2-drug STRs. These are hoped to have reduced toxicities and side effects as a result,” said Anaelle Tannen, Infectious Disease Analyst at GlobalData.
Six products are currently in Phase III development and are expected to launch by 2033, including four two-drug STRs.
These are Gilead Sciences’ (Gilead) once-daily combination of bictegravir and lenacapavir, Merck’s once-daily doravirine and islatravir, Gilead’s once-weekly islatravir and lenacapavir, and a once-weekly regimen of GS-1720 and GS-4182 developed jointly by Gilead and Merck.
“Currently, all STRs require daily administration and there is a need for alternative and more convenient options for patients which islatravir+lenacapavir and GS-1720+GS-4182 could address,” said Tannen.
Other notable therapies in late-stage development include CytoDyn’s once-weekly leronlimab, which is expected to be used in patients with CCR5-type virus, and Gilead’s biannual injectable lenacapavir for pre-exposure prophylaxis (PrEP).
Long-acting injectable therapies will gain significant market share across the 7MM as this method requires infrequent dosing and is thus more convenient.
“Lenacapavir, for example, is initially expected to be administered subcutaneously biannually for PrEP, and clinical trials are underway to see its efficacy when administered once a year. Data from a Phase I trial has demonstrated lenacapavir’s potential when administered intramuscularly once yearly,” Tannen informed.
Subcutaneous lenacapavir has demonstrated 100 per cent efficacy in preventing new HIV infections and, thus, has shown its potential as an important new tool for PrEP.
However, subcutaneous lenacapavir is expected to be more expensive than daily oral PrEP and the key opinion leaders (KOLs) interviewed by GlobalData have highlighted that this may be a barrier to access.
—IANS
na/
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by BhaskarLive.in and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of BhaskarLive.in We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, BhaskarLive.in takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
